The Glide SDI provides a way to quickly, cleanly and simply inject solid formations of drugs and vaccines directly through the skin, opening a range of therapeutic options for treatments.
The needle-free Glide SDI presents opportunities to improve the delivery of drugs and vaccines to meet the following medical needs: Biologic drugs: for protein-based therapeutics that cannot be taken orally, Glide offers a means to inject stable, solid formulations - for example, insulin, erythropoietin.
Proprietary and generic drugs (novel or existing): opportunity to deliver stable solid formulations through the skin, improving drug delivery; offers product differentiation and patent extension options - for example, interferon alpha, interferon beta.
Self-administered drugs: quick, easy, clean and safe to use at home with minimal training; no sharps disposal required and stable solid formulation may not require refrigeration - for example, human growth hormone, migraine treatments.
Vaccines: solid injection requires no needle and avoids need for expensive and complicated packaging to transport fluid; solid formulation may not require refrigeration; easy, large-scale, low-cost manufacturing potential - for example, hepatitis B, measles, tuberculosis, influenza.
Emergency medicines: quick, easy and clean administration, can be carried out with minimal training; easy to store and carry, with long-term stability - for example, adrenalin, glucagon.
Biodefence: quick, easy and clean administration with minimal training; low-cost manufacture on a large scale; stable formulations can be stockpiled - for example, small pox and influenza vaccines.
Developing world healthcare challenges: heat-stable formulations (no cold-chain required); low-cost manufacture on large scale; quick, easy and clean administration with minimal training - for example, vaccines, paediatric formulations.
